Meanwhile long-term efficacy of the Pfizer and Moderna jabs largely holds up, though J&J’s data seems less convincing.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
The Danish group reports promising mid-stage data with its respiratory syncytial virus vaccine, but competition is fierce.
More real-world data emerge backing Covid-19 vaccine efficacy against the Delta variant, and some will see Moderna’s Spikevax as a clear winner.